GE HealthCare to Acquire Intelerad for $2.3B

Shots: GE HealthCare has entered into an agreement to acquire Intelerad, expanding its cloud-enabled & AI-powered solutions portfolio As per the deal, GE HealthCare will acquire Intelerad for a purchase price of $2.3B in cash; closing is expected in H1’26 Acquisition will add Intelerad’s cloud-enabled radiology & cardiology imaging platforms & outpatient enterprise workflow solutions…

ByRidhi RastogiNovember 21, 2025

NEWS

Novartis to Acquire Avidity Biosciences for ~$12B, Boosting its Neuroscience Pipeline

Shots: Novartis has agreed to acquire Avidity Biosciences, strengthening its neuroscience pipeline with Avidity’s Antibody Oligonucleotide Conjugates (AOCs) platform & 3 late-stage programs As per the deal, Novartis will acquire Avidity for $72/share, valuing the company at ~$12B with an enterprise value of ~$11B; closing expected in H1’26 Before the merger, Avidity will transfer its early-stage precision…

ByRidhi RastogiOctober 27, 2025

NEWS

Abbott Secures European CE Mark for Volt PFA System to Treat Atrial Fibrillation

Shots: Abbott has received European CE Mark for its Volt PFA System to treat pts with atrial fibrillation; commercialization has begun, with further expansion in EU markets expected by H2’25 Approval was based on CE Mark study in the EU & Australia, showing that the Volt achieved pulmonary vein isolation (PVI) in 99.1% veins with…

ByRidhi RastogiMarch 28, 2025

INSIGHTS+

Know Your Investor (March Edition): Qiming Venture Partners

Shots: In this reprise, we feature Qiming Venture Partners again, based on the investments in 2023. With more than 600 investments to date, Qiming boasts a strong portfolio of companies involved in Technology & Consumer and Healthcare In 2023, Qiming closed 38 funding rounds comprising 11 in the first quarter, 10 in the second, 11…

BySenior EditorMarch 26, 2024

INSIGHTS+

Insights+: EMA Marketing Authorization of New Drugs in February 2024

Shots: The EMA approved 5 BLA and 8 New Chemical Entities in February 2024, leading to treatments for patients and advances in the healthcare industry In February 2024, the major highlighted drugs were Reblozyl to treat Transfusion-Dependent Anemia and Velsipity for the treatment of Severely Active Ulcerative Colitis PharmaShots has compiled a list of a total…

BySenior EditorMarch 20, 2024

TOP 20

Top 20 Immunology Companies Based on 2022 Immunology Segment Total Revenue

Shots: With the noble responsibility of ensuring a healthy society on their shoulders, biopharma companies focused on Immunology are diligently working to develop treatments, vaccines, antibodies, and drugs The global Immunology market was valued at $97.93B in 2021 and is anticipated to reach $184.21B by 2029 with a CAGR of 8.5 percent. In 2022, AbbVie…

ByPrince GiriAugust 14, 2023

GE HealthCare to Acquire Intelerad for $2.3B

Novartis to Acquire Avidity Biosciences for ~$12B, Boosting its Neuroscience Pipeline

Abbott Secures European CE Mark for Volt PFA System to Treat Atrial Fibrillation

Know Your Investor (March Edition): Qiming Venture Partners

Insights+: EMA Marketing Authorization of New Drugs in February 2024

Top 20 Immunology Companies Based on 2022 Immunology Segment Total Revenue

Contact US

FOLLOW US